Sugi Predict

Sugi Predict / Compounds / SCHEMBL22845199

SCHEMBL22845199

SCHEMBL22845199

CNC(=O)c1ccc(-n2c(=O)c3c(n4ncc(Cc5ccccc5)c24)CN(C(=O)c2ccc(Cl)c(Cl)c2)CC3)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 5/20 0.37
▸ MAPT P10636 4/20 0.37
▸ ALDH1A1 P00352 2/20 0.37
▸ GAA P10253 1/20 0.37
▸ HTT P42858 3/20 0.36
▸ NPSR1 Q6W5P4 1/20 0.36
▸ SMN1; SMN2 Q16637 3/20 0.36
▸ POLB P06746 1/20 0.35
▸ HDAC1 Q13547 1/20 0.34
▸ HDAC10 Q969S8 1/20 0.34
▸ HDAC8 Q9BY41 1/20 0.34
▸ HDAC6 Q9UBN7 1/20 0.34
▸ CRBN Q96SW2 1/20 0.34
▸ PARP1 P09874 1/20 0.34
▸ PARP2 Q9UGN5 1/20 0.34
▸ TACR3 P29371 1/20 0.33
▸ TP53 P04637 1/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ RECQL P46063 1/20 0.33
▸ KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24483838 0.94 HDAC1 (0.35) LMNAMAPTALDH1A1GAAHDAC1
SCHEMBL26842628 0.93 HTR1A (0.34) LMNAMAPTALDH1A1NPSR1SMN1; SMN2
SCHEMBL22845286 0.93 LMNA (0.40) LMNAMAPTALDH1A1GAAHTT
SCHEMBL26842626 0.93 LMNA (0.40) LMNAMAPTALDH1A1GAAHTT
SCHEMBL22845275 0.91 AR (0.36) —
SCHEMBL22845209 0.91 MAPT (0.42) LMNAMAPTALDH1A1GAAHTT
SCHEMBL22845379 0.90 PREP (0.36) LMNAMAPTALDH1A1GAAHTT
SCHEMBL22845200 0.89 GCGR (0.38) MAPTPOLB
SCHEMBL24469883 0.88 MGLL (0.36) LMNAMAPTALDH1A1SMN1; SMN2HDAC1
SCHEMBL22845519 0.87 MTHFD2 (0.35) LMNAMAPTALDH1A1GAAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11820773-B2 Tricyclic compounds ALIGOS THERAPEUTICS, INC. (US) 2023-11-21 — — US disclosed
US-11820773-B2 Tricyclic compounds ALIGOS THERAPEUTICS, INC. (US) 2023-11-21 — — US disclosed
WO-2022115384-A1 TRICYCLIC COMPOUNDS ALIGOS THERAPEUTICS, INC. (US) 2022-06-02 — — WO disclosed
US-20220169650-A1 TRICYCLIC COMPOUNDS ALIGOS THERAPEUTICS, INC. 2022-06-02 — — US disclosed
US-20220000874-A1 TRICYCLIC COMPOUNDS ALIGOS THERAPEUTICS, INC. 2022-01-06 — — US disclosed
US-11136321-B2 Tricyclic compounds ALIGOS THERAPEUTICS, INC. (US) 2021-10-05 — — US disclosed
US-20200407361-A1 TRICYCLIC COMPOUNDS ALIGOS THERAPEUTICS, INC. 2020-12-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220169650-A1 TRICYCLIC COMPOUNDS SLC10A1, PKD1, CEL LMNA 1680/4885MAPT 651/4885ALDH1A1 648/4885
US-20220000874-A1 TRICYCLIC COMPOUNDS SLC10A1, PKD1, CEL LMNA 1680/4885MAPT 651/4885ALDH1A1 648/4885
US-11136321-B2 Tricyclic compounds SLC10A1, PKD1, CEL LMNA 1680/4885MAPT 651/4885ALDH1A1 648/4885
US-11820773-B2 Tricyclic compounds SLC10A1, PKD1, CEL LMNA 1680/4885MAPT 651/4885ALDH1A1 648/4885
US-20200407361-A1 TRICYCLIC COMPOUNDS SLC10A1, PKD1, CEL LMNA 1680/4885MAPT 651/4885ALDH1A1 648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.